<code id='F42B23D559'></code><style id='F42B23D559'></style>
    • <acronym id='F42B23D559'></acronym>
      <center id='F42B23D559'><center id='F42B23D559'><tfoot id='F42B23D559'></tfoot></center><abbr id='F42B23D559'><dir id='F42B23D559'><tfoot id='F42B23D559'></tfoot><noframes id='F42B23D559'>

    • <optgroup id='F42B23D559'><strike id='F42B23D559'><sup id='F42B23D559'></sup></strike><code id='F42B23D559'></code></optgroup>
        1. <b id='F42B23D559'><label id='F42B23D559'><select id='F42B23D559'><dt id='F42B23D559'><span id='F42B23D559'></span></dt></select></label></b><u id='F42B23D559'></u>
          <i id='F42B23D559'><strike id='F42B23D559'><tt id='F42B23D559'><pre id='F42B23D559'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:442
          Adobe

          Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial. 

          The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

          advertisement

          “We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          Biotech venture capitalists face new demands from investors
          Biotech venture capitalists face new demands from investors

          AdobeOverthelastyearortwo,somethingcurioushasstartedoccurringintheconferenceroomsandprivateZoommeeti

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          EU regulator recommends expanding Mounjaro approval to obesity

          PauloAmorim/VWPicsviaAPImagesLONDON—TwodaysaftersimilardecisionsintheU.S.andU.K.,regulatorsinEuropeo